Jianfeng Group Lin2015 -001 (Announcement of Jianfeng Group on Progress of Naisikang)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2015-001
Bond Abbreviations: 13 Spike 01 Bond Code: 122227
Bond Abbreviations: 13 Spike 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Progress Announcement on Jianfeng Pharmaceutical's Acquisition of Naisikang's Equity
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
2014 7 29 , the company once announced that Zhejiang Jianfeng pharmaceutical co., ltd., the controlling subsidiary of the company, signed the "framework agreement on equity transfer of Zhejiang nesikang pharmaceutical co., ltd." (hereinafter referred to as the "framework agreement") with Creative Medicine and Xi' an zizhitong investment co., ltd, it is proposed to transfer its 70% and 25% stake in Zhejiang Niskang Pharmaceutical Co., Ltd. For the above matters, please refer to the "Prompt Announcement of Zhejiang Jianfeng Group Co., Ltd. on Signing of Equity Transfer Framework Agreement by Subsidiaries" issued by the Company on , , , , , , , ,
.After the framework agreement was signed, according to the agreement, we hired audit, evaluation and other intermediary agencies with securities qualification to conduct a comprehensive audit, evaluation and due diligence on Zhejiang Nestkang Pharmaceutical Co., Ltd. , and conducted many consultations and negotiations with the equity transferor, however, due to the failure to solve the environmental protection problems of
Zhejiang Naisikang Pharmaceutical Co., Ltd., a consensus could not be reached.In view of the fact that the exclusive period stipulated in the Framework Agreement has expired, after friendly negotiation, all parties jointly decided to terminate the equity transfer of Nessikang Company. On April 13, 2015, parties
signed the Memorandum on Termination of the Framework Agreement on Equity Transfer of Zhejiang Nessikang Pharmaceutical Co., Ltd. The main contents of the memorandum are as follows:1. The parties agree to terminate the Framework Agreement on Equity Transfer of Zhejiang Nestkang Pharmaceutical Co., Ltd. signed on July 28, 2014.
2. Each party shall bear the expenses (audit and evaluation expenses) paid for the above-mentioned equity transfer, and shall not claim compensation or compensation from the other party.
3. Creative Medicine and Xi 'an Zizhitong Investment Co., Ltd. may seek a third party to contact, negotiate and negotiate the above-mentioned equity transfer of Zhejiang Naisikang Pharmaceutical Co., Ltd.
The termination of the equity transfer of Zhejiang Naisikang Pharmaceutical Co., Ltd.
will not have a material adverse impact on the production and operation of the Company.is hereby announced
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page